Amicus Therapeutics, Inc. (FOLD)

The consensus price target hints at a 60.6% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin...

Today, we explore how investors can find the best-in-class cheap stocks trading for under $10 a share to buy now....

Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions....

FOLD leans on rising Galafold sales on the back of strong commercial execution as momentum builds into 2026....

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?...

The average of price targets set by Wall Street analysts indicates a potential upside of 58.5% in Amicus Therapeutics (FOLD). While the effectiveness of this highly sought-after metric is questionable...

AXQ Capital LP purchased a new position in Amicus Therapeutics, Inc. (NASDAQ: FOLD) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commi...

Amicus Therapeutics (FOLD) is progressing toward profitability, driven by strong Q3 results and expanding global approvals for its rare disease therapies. FOLD's revenue grew 19.5% year-over-year, wit...

Amicus Therapeutics, Inc. ( FOLD ) UBS Global Healthcare Conference 2025 November 10, 2025 2:45 PM EST Company Participants Jeffrey Castelli - Chief Development Officer Presentation Unknown Analyst Gr...

The consensus price target hints at a 76.3% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin...